The U.S Food and Drug Administration (FDA) has approved four CD19-CAR T products for relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (2), r/r large B-cell lymphoma (6, 7) and mantle cell lymphoma (8). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.